An Italian single-center randomized phase II clinical study (NCT04113863) is presently investigating preoperative activity of ATRA in HR+/HER2- early breast cancer in combination with non-steroidal aromatase inhibitor anastrozole. Here, ERBB2 is linked to breast cancer.